Opioid Antagonist Market Size & Share, by Drug Type (Buprenorphine, Naltrexone, Bunavail); End User (Hospitals, Private Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3179
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Companies Dominating the Opioid Antagonist Landscape

top-features-companies
    • Indivior PLC 
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • •Regional Presence
      • SWOT Analysis
    • Alkermes.
    • Titan Pharmaceuticals, Inc.
    • Hikma Pharmaceuticals PLC
    • Orexo AB 
    • Camurus AB
    • Acura Pharmaceuticals. 
    • Collegium Pharmaceutical          
    • AstraZeneca
    • Viatris Inc.
    • Catalent, Inc

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • A commercial supply agreement has been signed by Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making affordable naloxone available to everyone, and Catalent, the global leader in enabling the development and supply of better treatments for patients. As per the agreement, Catalent will produce RiViveTM (3.0 mg) naloxone nasal spray from Harm Reduction Therapeutics for the urgent treatment of confirmed or suspected opioid overdoses.
  • The U.S. Food and Drug Administration ("FDA") has approved Titan Pharmaceuticals, Inc.'s application for an Investigational New Drug ("IND") study of its subdermal formulation of nalmefene, an opioid antagonist, for up to six months or longer. The purpose of the formulation is to prevent relapse in adults with opioid use disorder ("OUD") after they have completed opioid detoxification.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3179
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increased investments in healthcare, rising awareness, and increase in public health initiatives are some of the major growth drivers for the opioid antagonist market.

The market size of opioid antagonists is anticipated to attain a CAGR of 13% over the forecast period, i.e., 2024-2036.

The major players in the market are Alkermes., Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Orexo AB, Camurus AB, Acura Pharmaceuticals., Collegium Pharmaceutical, AstraZeneca, Viatris Inc., Catalent, and others.

The Buprenorphine segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying